daiichi-acquires-controlling-stake-in-ranbaxy

Daiichi acquires controlling stake in Ranbaxy

The Japanese buyer aims to increase its initial stake in IndiaÆs largest pharmaceutical company to 50.1% for a total outlay of up to $4.6 billion.
Japanese pharmaceutical major Daiichi Sankyo will acquire a controlling interest in IndiaÆs largest pharmaceutical company Ranbaxy Laboratories at a price that values the Indian company at $8.5 billion.

The founders and controlling shareholders of Ranbaxy, the Singh family, have agreed to sell their 34.8% interest to Daiichi Sankyo at a price of Rs737 $17.17 a share. The deal, which also involves the issue of new shares and warrants to Daiichi, will precipitate an open offer to other shareholders in Ranbaxy, in accordance with regulatory guidelines in India, for up to 20% more shares at the same price.

The agreed price of Rs737 represents a premium of 53.5% to RanbaxyÆs average daily closing price on the...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222